search
Back to results

Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Fexofenadine HCl + Pseudoephedrine HCl
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Human subjects aged between 18 and 45 years (including both)
  • Subjects'weight within the normal range according to normal values for the Body Mass Index (18.5 to 24.9kgm2)with minimum of 50 kg weight.
  • Subjects with normal health as determined by personal medical history clinical examination and laboratory examinations within the clinically acceptable normal range.
  • Subjects having normal 12-lead electrocardiogram (ECG).
  • Subjects having normal chest X-Ray (P/A view).
  • Have a negative urine screen for drugs of abuse (including amphetamines,barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  • Have negative alcohol breath test.
  • Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion Criteria:

Subjects will be excluded from the study, if they meet any of the following criteria:

  • Hypersensitivity to Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride or related drugs.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  • History or presence of significant alcoholism or drug abuse in the past one year.
  • History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
  • History or presence of significant asthma, urticaria or other allergic reactions.
  • History or presence of significant gastric and/or duodenal ulceration.
  • History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
  • History or presence of cancer.
  • Difficulty with donating blood.
  • Difficulty in swallowing solids like tablets or capsules.
  • Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.
  • Diastolic blood pressure less than SO mm Hg or more than 90 mm Hg.
  • Pulse rate less than 50/minute or more than 100/minute.
  • Oral temperature less than 95°F or more than 98.5°F.
  • Respiratory rate less than 12/minute or more than 20/minute
  • SUbjects who have used any prescription medication, within 14 days of period 01 dosing or OTC medication within 14 days of period 01 dosing.
  • Major illness during 3 months before screening.
  • Participation in a drug research study within past 3 months.
  • Donation of blood in the past 3 months before screening.
  • Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to period 01 dosing.
  • Subjects who have consumed food or beverages containing grapefruit or pomelo within 14 days prior to period 01 dosing.

Sites / Locations

  • Veeda Clinical Research Pvt. Ltd.,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Fexofenadine HCl + Pseudoephedrine HCl

Allegra-D 24 hour ER Tablets

Arm Description

Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories

Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.

Outcomes

Primary Outcome Measures

Bioequivalence based on Cmax and AUC parameters

Secondary Outcome Measures

Full Information

First Posted
May 27, 2010
Last Updated
June 11, 2010
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01133483
Brief Title
Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions
Official Title
An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fed Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Completed
Study Start Date
April 2007 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to Compare and evaluate the single dose, crossover, bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets and Allegra-D 24 hr tablets. Monitor the adverse events and ensure the safety of subjects.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA in healthy, adult, human subjects under fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fexofenadine HCl + Pseudoephedrine HCl
Arm Type
Experimental
Arm Description
Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
Arm Title
Allegra-D 24 hour ER Tablets
Arm Type
Active Comparator
Arm Description
Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
Intervention Type
Drug
Intervention Name(s)
Fexofenadine HCl + Pseudoephedrine HCl
Other Intervention Name(s)
Allegra-D 24 hour ER Tablets
Intervention Description
Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
Primary Outcome Measure Information:
Title
Bioequivalence based on Cmax and AUC parameters
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Human subjects aged between 18 and 45 years (including both) Subjects'weight within the normal range according to normal values for the Body Mass Index (18.5 to 24.9kgm2)with minimum of 50 kg weight. Subjects with normal health as determined by personal medical history clinical examination and laboratory examinations within the clinically acceptable normal range. Subjects having normal 12-lead electrocardiogram (ECG). Subjects having normal chest X-Ray (P/A view). Have a negative urine screen for drugs of abuse (including amphetamines,barbiturates, benzodiazepines, marijuana, cocaine, and morphine). Have negative alcohol breath test. Subjects willing to adhere to the protocol requirements and to provide written informed consent. Exclusion Criteria: Subjects will be excluded from the study, if they meet any of the following criteria: Hypersensitivity to Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride or related drugs. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. History or presence of significant alcoholism or drug abuse in the past one year. History or presence of significant smoking (more than 10 cigarettes or beedi's/day). History or presence of significant asthma, urticaria or other allergic reactions. History or presence of significant gastric and/or duodenal ulceration. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour. History or presence of cancer. Difficulty with donating blood. Difficulty in swallowing solids like tablets or capsules. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg. Diastolic blood pressure less than SO mm Hg or more than 90 mm Hg. Pulse rate less than 50/minute or more than 100/minute. Oral temperature less than 95°F or more than 98.5°F. Respiratory rate less than 12/minute or more than 20/minute SUbjects who have used any prescription medication, within 14 days of period 01 dosing or OTC medication within 14 days of period 01 dosing. Major illness during 3 months before screening. Participation in a drug research study within past 3 months. Donation of blood in the past 3 months before screening. Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to period 01 dosing. Subjects who have consumed food or beverages containing grapefruit or pomelo within 14 days prior to period 01 dosing.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Dharmesh Domadia
Organizational Affiliation
Veeda Clinical Research Pvt. Ltd.,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Veeda Clinical Research Pvt. Ltd.,
City
Ahmedabad
State/Province
Gujrat
ZIP/Postal Code
380015
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions

We'll reach out to this number within 24 hrs